Related Experiment Video
Updated: Jun 15, 2026
03:55
Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer
Published on: June 9, 2023
Current concepts and future directions in differentiated thyroid cancer.
1Department of Endocrinology and Internal Medicine, Royal Brisbane & Women's Hospital, Herston, Qld 4029, Australia. donald.mcleod@gmail.com
The Clinical Biochemist. Reviews
|February 25, 2010
Summary
Differentiated thyroid cancer (DTC) incidence is rising, necessitating evolving management strategies. Clinical chemistry is vital for monitoring DTC, with ongoing research into molecular diagnostics and improved therapies.
Area of Science:
- Endocrinology
- Oncology
- Clinical Chemistry
Background:
- Differentiated thyroid cancer (DTC) incidence is increasing globally.
- Current management strategies for DTC are evolving.
- Clinical chemistry plays a crucial role in DTC diagnosis and monitoring.
Purpose of the Study:
- To provide an overview of DTC biology, monitoring, and management.
- To highlight the relevance of clinical chemistry in DTC protocols.
- To discuss current limitations and future directions in DTC management.
Main Methods:
- Literature review on DTC biology, epidemiology, and clinical management.
- Analysis of the role of clinical chemistry assays in DTC follow-up.
- Discussion of emerging molecular targets and diagnostic tools.
Main Results:
- DTC incidence is on the rise, requiring updated management approaches.
- Clinical chemistry techniques are integral to current DTC monitoring protocols.
- Technical limitations in monitoring tools exist but are being addressed.
Conclusions:
- Continued advancements in understanding DTC biology are crucial.
- Clinical chemistry will remain central to effective DTC patient management.
- Molecular insights offer potential for improved DTC diagnosis and therapy.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:27Hyperthyroidism II: Pathophysiology
Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH receptors...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:24Graves Disease II: Pathophysiology
Graves’ disease is an autoimmune disorder characterized by the production of thyroid-stimulating immunoglobulins (TSI) that activate TSH receptors, leading to excessive synthesis and release of thyroid hormones (T3 and T4) and resulting in hyperthyroidism.Among all causes of hyperthyroidism, Graves’ disease is the most common and can happen at any age, though it is more frequent in women. It produces a hypermetabolic state with features such as weight loss, tachycardia, tremor, and heat...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...